(Q44963400)

7 December 2017

title

Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies (English)

1 reference

7 December 2017

Timothy Mathew

1

1 reference

7 December 2017

Henri Kreis

series ordinal

2

1 reference

7 December 2017

Peter Friend

series ordinal

3

1 reference

7 December 2017

language of work or name

1 reference

1 August 2004

1 reference

7 December 2017

published in

Clinical Transplantation

1 reference

7 December 2017

volume

18

1 reference

7 December 2017

issue

4

1 reference

7 December 2017

page(s)

446-449

1 reference

Cyclosporine induces cancer progression by a cell-autonomous mechanism.

7 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2004.00188.X

Malignancy after renal transplantation: analysis of incidence and risk factors in 1700 patients followed during a 25-year period

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2004.00188.X

Activation of p70 ribosomal protein S6 kinase is an essential step in the DNA damage-dependent signaling pathway responsible for the ultraviolet B-mediated increase in interstitial collagenase (MMP-1) and stromelysin-1 (MMP-3) protein levels in huma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2004.00188.X

Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2004.00188.X

Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2004.00188.X

A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2004.00188.X

Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2004.00188.X

Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2004.00188.X

Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2004.00188.X

Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2004.00188.X

Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-0012.2004.00188.X

10.1111/J.1399-0012.2004.00188.X

21 January 2018

Identifiers

DOI

1 reference

7 December 2017

1 reference